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doi:10.1016/j.jmii.2010.07.001Influenza A “novel H1N1” with severe acute respiratory distress syndrome (ARDS) is a serious
illness that poses a challenge to clinicians managing such cases. This case report reveals
a patient with ARDS secondary to influenza A with deteriorating clinical status, who improved
tremendously after intravenous immunoglobulin G (IV IgG). Patients with H1N1 associated with
ARDS may be given a trial of IV IgG. More case reports and trials are required to ascertain the
efficacy of IV IgG and the best dosage and timing of starting IV IgG in relation to antiviral
therapy.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The 2009 flu pandemic is a global outbreak of a new strain
of an influenza A virus subtype H1N1, referred to as the
“novel H1N1,” first identified in Mexico in April 2009.1 Since
then, the disease spread to all continents, and in June
2009, The World Health Organization (WHO) raised the
pandemic alert level to Phase 6.2 Till December 11, 2009,of Medicine, Hospital Tengku
5100 Kuantan, Pahang Darul
il.com (J.L. Chong).
an Society of Microbiology. Publmore than 207 countries had reported laboratory-confirmed
cases of pandemic influenza H1N1 2009, including at least
8,768 deaths.3 In Malaysia, the total number of deaths
reported was 77.4 Clinicians face a great challenge in
treating patients with influenza A complicated by ARDS,
who require ventilation, as some of these cases do not seem
to respond well to conventional therapy. Hence, trials of
new modalities of treatment and researches on the path-
ophysiology of ARDS associated with influenza A are
essential in improving treatment outcome. Here, we report
the case of a patient who was successfully treated with
antiviral therapy, mechanical ventilation, and intravenous
immunoglobulin G (IV IgG), even though he was initially
given a bad prognosis.ished by Elsevier Taiwan LLC. All rights reserved.
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A 59-year-old male patient presented to the district
hospital in August 2009 with a history of high-grade fever
and sore throat for 4 days. Apart from the fever, he com-
plained of tiredness, reduced appetite, and difficulty in
breathing, 2 days before presentation. There was no diar-
rhea, vomiting, cough, runny nose, or body ache. He has no
known prior medical illness.
At the district hospital, the patient was treated for
pneumonia, but on Day 3 of admission, the patient’s
condition deteriorated. He was then transferred to this
hospital for further management. On arrival, he was
tachypneic, dehydrated, and restless; respiratory rate was
40 breaths/min; temperature was 39.5C; oxygen satura-
tion was 86e88% on room air and 92e93% on high-flow
mask; blood pressure was 177/72 mmHg; and pulse rate was
93 beats/min. Examination of the respiratory system
revealed generalized crepitations, no rhonchi, and equal
breath sound in both lungs. Examinations of the cardio-
vascular, abdominal, and neurological systems were
unremarkable.
Laboratory tests revealed that the arterial blood gas on
high-flow mask showed compensated hypoxia with PaO2 of
57.9 mmHg and O2 saturation of 92.5%; the white cell count
was 4.38 109/L (neutrophil, 77.1%; lymphocyte, 17.1%;
monocyte, 5.3%; eosinophil, 0.0%; basophil 0.5%). Chest
radiograph showed bibasal consolidation. Other investiga-
tion results are shown in Table 1. The patient wasFigure 1. Chest radiographs show (A) bibasal pathy opacity on D
upper zone on Day 13 of illness (Day 6 of oseltamivir 150 mg bd, p
illness (1 day after completion of IV IgG for 5 days); and (D) minimimmediately sent to the intensive care unit and intubated
and ventilated with the diagnosis of influenza-like illness
and differential diagnosis of community-acquired pneu-
monia. He was started on oral oseltamivir 150 mg twice
daily, IV ceftriaxone 2 g immediately and 1 g daily, and IV
azithromycin 500 mg daily.
Despite adequate treatment with double dose of osel-
tamivir, antibiotic administration, and no evidence of
secondary infection, the patient’s condition worsened, as
evidenced by the ventilator setting change from synchro-
nized intermittent mandatory ventilation to BiLevel mode
on Day 4 of admission, with FiO2 of 0.5, high/low positive
end expiratory pressure of 28/12 mmHg, and pO2 of only
79 mmHg on Day 6 of admission, and serial chest radio-
graphs showed worsening opacity up to the upper zone
(Fig. 1). Blood culture and sensitivity taken on the day of
admission grew Gram-positive cocci coagulaseenegative
staphylococcus (sensitive to ampicilin, erythromycin, fusi-
dic acid, gentamycin, penicillin, oxacillin, and trimetho-
prinesulfamethoxazole), endotracheal culture and
sensitivity was negative. Real-time polymerase chain
reaction result eventually showed novel flu A H1N1 swine
lineage, and with the symptoms, he fulfilled the WHO
criteria for the diagnosis of a confirmed case of pandemic
(H1N1) 2009.5
On Day 6 of admission, the decision was made to
administer 36 g IV IgG (patient’s weight was 90 kg) for
a planned duration of 5 days. This was the first patient in
this hospital who was treated with IV IgG for ARDSay 7 of illness (Day 1 of admission); (B) worsening opacity up to
reeIV IgG); (C) improvement of chest radiograph on Day 19 of
al pulmonary fibrosis 2 months after discharge.
Table 1 Blood investigations and ventilator setting
Investigation D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14
Hemoglobin
(g/dL)
14.0 13.3 12.1 12.4 11.7 11.4 11.6 11.5 11.4 11.7 11.0 10.5 103 10.9
White cell count 4.4 6.7 7.6 8.8 11.5 11.5 9.7 10.0 11.6 12.5 16.5 17.2 15.8 15.2
Platelet 139 147 146 170 234 250 316 340 430 508 587 719 800 880
Urea (mmol/L) 3.2 3.7 4.8 4.7 5.6 5.8 5.3 5.1 5.2 5.6 6.3 8.7 9.3 8.5
Creatinine
(mmol/L)
81 91 73 80 82
Calcium
(mmol/L)
1.81 1.77 1.96 1.98 2.13
AST (u/L) 211 138 110 166 182 162 74
ALT (u/L) 97 81 72 150 200 290 198
ALP (u/L) 45 61 73 131 168 177 126
Bilirubin
(umol/L)
9.0 8.5 15.1 22.3 22.8 18.0 25.9
Ventilator setting Ventilator mode
SIMV SIMV SIMV BiLevel BiLevel BiLevel BiLevel BiLevel SIMV SIMV CPAP VM60 VM40 NPO2
FiO2 1.0 0.8 0.7 0.5 0.5 0.5 0.5 0.4 0.4 0.4 0.4 60% 40% 3 L
PEEP (mmHg) 8 10 10 28/12 28/12 24/10 26/12 26/10 12 10 6 d d d
Pressure support
(mmHg)
12 12 12 12 12 12 12 12 12 8.6 10 d d d
SpO2 (%) 98 98 97 98 97 94 97 96 96 97 99 99 100 98
pH 7.38 7.38 7.39 7.37 7.36 7.38 7.42 7.37 7.39 7.36 7.41 7.41 7.38 7.38
PaCO2 (mmHg) 33.4 31.5 36.7 38.8 39.2 38.9 34.2 39.2 38.5 41.5 34.7 32.6 36.2 37.8
PaO2 (mmHg) 138 104 74 79 79 90 85 76 101 82 111 125 120 79.6
Bicarbonate
(mmol/L)
21 20 22 22 22 23 23 23 23 23 23 22 22 22
ALPZ alkaline phosphatase; ALTZ alanine aminotransferase; ASTZ aspartate transaminase; CPAPZ continuous positive airway
pressure; FiO2Z fraction of inspired oxygen; NPO2Z nasal prong oxygen; PEEPZ positive end expiratory pressure; SIMVZ synchronized
intermittent mandatory ventilation; SpO2Z oxygen saturation; VM40Z venture mask 40%; VM60Z venture mask 60%.
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encouraging response with improvement of ventilator
setting (Table 1). He was extubated on Day 2 post-
completion of IV IgG (Day 19 of illness) and discharged after
20 days of admission. On subsequent follow-up in the
outpatient clinic 2 months later, his functional status was
back to normal, and his chest radiograph revealed minimal
pulmonary fibrosis (Fig. 1).Discussion
Intravenous immune globulin (IVIG) contains the pooled IgG
immunoglobulins (antibodies) extracted from the plasma of
more than 1,000 blood donors. The precise mechanism by
which IVIG suppresses harmful inflammation has not been
definitively established but is believed to involve the
inhibitory Fc receptor.6,7 The donor antibody may bind
directly with the abnormal host antibody, stimulating its
removal. Alternatively, the massive quantity of antibody
may stimulate the host’s complement system, leading to
enhanced removal of all antibodies, including the harmful
ones. IVIG also blocks the antibody receptors on immune
cells (macrophages), leading to decreased damage by these
cells, or regulation of macrophage phagocytosis. IVIG may
also regulate the immune response by reacting witha number of membrane receptors on T cells, B cells, and
monocytes that are pertinent to autoreactivity and induc-
tion of tolerance to self.8
In 2003, Morishima T9 from Japan reported that
a combination of antivirals, high-dose gamma-grobulin,
steroid pulse therapy, high-dose Antithrombin III, head
cooling, and plasma exchange, could reduce the mortality
of pediatric patients with influenza-associated encepha-
lopathy. Satoshi H10 et al. demonstrated that high-dose IVIG
(1,000 mg/kg) decreased the mortality and pulmonary
pathology in a rat model of sepsis.
Despite the fact that data regarding IVIG in severe H1N1
infections was limited, one study had reported significant
neutralizing activity of human IVIG preparations against the
pandemic H1N1 virus.11 Another observation by researchers
was the association of low total immunoglobulin subclass
levels, particularly IgG2, in both pregnant and nonpregnant
H1N1 2009 patients who developed respiratory failure.12 In
management of this case, IV IgG was administered on the
basis of its potential immune-modulator properties and
neutralizing antibodies, which may partly contribute to
a favorable outcome of this patient.
In conclusion, this patient was successfully treated with
a combination of 0.4 g/kg IV IgG and double dose of oselta-
mivir. Patients with H1N1 associated with ARDSmay be given
a trial of IV IgG. More case reports and trials are required to
322 J.L. Chong et al.ascertain the efficacy of IV IgG and the best dosage and
timing of starting IV IgG in relation to antiviral therapy.
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